JP2023505222A5 - - Google Patents
Info
- Publication number
- JP2023505222A5 JP2023505222A5 JP2022533442A JP2022533442A JP2023505222A5 JP 2023505222 A5 JP2023505222 A5 JP 2023505222A5 JP 2022533442 A JP2022533442 A JP 2022533442A JP 2022533442 A JP2022533442 A JP 2022533442A JP 2023505222 A5 JP2023505222 A5 JP 2023505222A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- lesion
- cancer
- pharmaceutical product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945053P | 2019-12-06 | 2019-12-06 | |
| US62/945,053 | 2019-12-06 | ||
| PCT/US2020/063444 WO2021113734A1 (en) | 2019-12-06 | 2020-12-04 | Methods for enhancing immunity and tumor treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023505222A JP2023505222A (ja) | 2023-02-08 |
| JP2023505222A5 true JP2023505222A5 (https=) | 2023-12-12 |
Family
ID=73856374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533442A Pending JP2023505222A (ja) | 2019-12-06 | 2020-12-04 | 免疫増強および腫瘍処置のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230028062A1 (https=) |
| EP (1) | EP4069300A1 (https=) |
| JP (1) | JP2023505222A (https=) |
| CN (1) | CN115052631A (https=) |
| TW (1) | TW202133886A (https=) |
| WO (1) | WO2021113734A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2889904T3 (es) | 2015-08-18 | 2022-01-14 | Rakuten Medical Inc | Conjugados de colorante de ftalocianina y su almacenamiento |
| JP2024505556A (ja) * | 2021-02-02 | 2024-02-06 | ラクテン・メディカル，インコーポレイテッド | がん、腫瘍および腫瘍細胞の局所および全身処置のための方法 |
| AU2023221861A1 (en) * | 2022-02-18 | 2024-09-05 | Rakuten Medical, Inc. | Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use |
| CN115364238B (zh) * | 2022-08-16 | 2024-02-02 | 山东大学 | 一种阿特珠单抗-mmad结合物及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US11154620B2 (en) * | 2015-08-18 | 2021-10-26 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
| ES2889904T3 (es) * | 2015-08-18 | 2022-01-14 | Rakuten Medical Inc | Conjugados de colorante de ftalocianina y su almacenamiento |
| CA3070469C (en) | 2016-10-25 | 2022-06-21 | Rakuten Medical, Inc. | Light diffusing devices for use in photoimmunotherapy |
| US10416366B2 (en) | 2016-10-25 | 2019-09-17 | Rakuten Medical, Inc. | Light diffusing devices for use in photoimmunotherapy |
| JP2020508323A (ja) * | 2017-02-23 | 2020-03-19 | ラクテン メディカル インコーポレイテッド | 光免疫療法のための治療用組成物および関連する方法 |
| CN115943306A (zh) * | 2019-03-29 | 2023-04-07 | 乐天医药生技股份有限公司 | 用于光免疫疗法的方法和相关生物标志物 |
| CN114423453A (zh) * | 2019-07-30 | 2022-04-29 | 乐天医药生技股份有限公司 | 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit) |
-
2020
- 2020-12-04 CN CN202080095859.9A patent/CN115052631A/zh active Pending
- 2020-12-04 US US17/782,111 patent/US20230028062A1/en active Pending
- 2020-12-04 TW TW109142933A patent/TW202133886A/zh unknown
- 2020-12-04 WO PCT/US2020/063444 patent/WO2021113734A1/en not_active Ceased
- 2020-12-04 EP EP20828490.1A patent/EP4069300A1/en active Pending
- 2020-12-04 JP JP2022533442A patent/JP2023505222A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huinen et al. | Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes | |
| Hu et al. | Combined radiation therapy and immune checkpoint blockade therapy for breast cancer | |
| Lee et al. | Advancements in small cell lung cancer | |
| Du et al. | PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes | |
| JP2023505222A5 (https=) | ||
| Chang et al. | Interventional therapy combined with immune checkpoint inhibitors: emerging opportunities for cancer treatment in the era of immunotherapy | |
| Chen et al. | Driving CARs on the uneven road of antigen heterogeneity in solid tumors | |
| Ferris et al. | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation | |
| Hovhannisyan et al. | CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks | |
| Golden et al. | Radiotherapy and immunogenic cell death | |
| Al Jarroudi et al. | Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases | |
| Gupta et al. | Clinical activity of ipilimumab plus nivolumab in patients with metastatic non–clear cell renal cell carcinoma | |
| Cushman et al. | Combining radiation plus immunotherapy to improve systemic immune response | |
| Cai et al. | Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression | |
| Jason et al. | Integration of radiation and immunotherapy in breast cancer-treatment implications | |
| JP2022543765A5 (https=) | ||
| Gervaso et al. | Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe? | |
| Chavez et al. | Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia | |
| WO2023095929A1 (ja) | 悪性腫瘍治療薬 | |
| Fleischmann et al. | Radioimmunotherapy: future prospects from the perspective of brachytherapy | |
| Serre et al. | Brachytherapy: perspectives for combined treatments with immunotherapy | |
| JP7614690B1 (ja) | 腫瘍微小環境をターゲットとする光免疫療法に用いる医薬組成物、治療効果確認のためのマーカー、及び検査方法 | |
| Xia et al. | Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma | |
| Gorwitz et al. | Zolbetuximab-clzb: targeting claudin 18.2 in advanced gastric and gastroesophageal adenocarcinoma | |
| Jin et al. | Photoimmunotheranostics of epithelioid sarcoma by targeting CD44 or EGFR |